GlassScriptPhysician profile
Shoaib Hashmi
NPI 1821191412
$5,203.07
in general payments reported to CMS, 2019-2025
40 companies · $589 in 2025
The $589 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $34.07 · 2021: $543 · 2022: $648 · 2023: $896 · 2024: $1,516 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,942 · Food and Beverage: $1,041 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,942.08 |
| Food and Beverage | $1,040.63 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $2,011.08 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $489.53 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $298.12 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $286.41 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $234.79 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $213.73 | 2019-2020 | |
| Nuvasive, INC. | $156.00 | 2021 | |
| Merck Sharp & Dohme LLC | $147.49 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Biogen, INC. | $118.87 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $117.67 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $89.62 | 2019 | |
| Lilly USA, LLC | $84.62 | 2022-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $74.61 | 2021-2024 | Rexulti |
| Astellas Pharma US INC | $60.17 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.57 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shoaib Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.